U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT07451795) titled 'SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC' on Dec. 24, 2025.
Brief Summary: The aim of this study is to evaluate the efficacy of SHR-1701 in combination with SBRT in patients with metastatic castration-resistant prostate cancer. Dr. Yao Zhu from Fudan University Shanghai Cancer Center is the co-leading PI of this study.
Study Start Date: March 02
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer
mCRPC (Metastatic Castration-resistant Prostate Cancer)
Intervention:
COMBINATION_PRODUCT: SHR-1701 + SBRT
Stereotactic body radiotherapy on targeted metastasis determined by MDT + SHR1701 30mg/kg IV eve...